Abdullah ATLİ, Abdullah ACAR, Eşref AKIL, Rezan ALP, Hasan H ÖZDEMİR

Epilepsi hastasında topiramatın indüklediği ekolali olgusu

Ekolali başkalarının söylediklerini anlamsız olarak tekrar edilmesi olan sözel bir davranış bozukluğudur. Topiramat birçok epileptik nöbet tipinin tedavisinde kullanılan etkili bir antiepileptik ajandır. Olgumuz 44 yaşında epileptik nöbetleri için 1000mg/gün sodyum valproat kullanan bir epilepsi hastası idi. Son aylarda nöbet sıklığında artma nedeniyle tedavisine yüksek dozda ve hızlı titre edilerek 600mg/gün dozunda topiramat eklendi. Topiramat eklendikten sonra epileptik nöbeti olmadı. Hasta topiramat kullanmaya başladıktan kısa bir süre sonra konfüzyon, dezoryantasyon ve özelikle ekolali içeren konuşma bozukluğu gelişti. Bu nedenle bir epilepsi hastasında topiramatın hızlı titrasyonunun sebep olduğu bir ekolali olgusunu sunduk.

A case of echolalia in a topiramate induced patient with epilepsy

Echolalia are subsets of imitative behavior which repetition of sounds and language. Topiramate is an effective drug for treatment several types of seizures. It is generally tolerated well. We reported the case of a 44-year old man patient who presented with a history of a epilepsy disorder, He had been maintained with 1000 mg/day sodium valproate for seizure episode. But this recently did not control his seizure episode. Then he was placed on topiramate (600mg/day). Following treatment, he had no seizure episode. subsequently He became incoherence, confusion, disorientation, and significant speech impairments including echolalia Thereby, we present a case of echolalia in a rapidly titrated topiramate induced in a epilepsy disorder patient.

PDF

___

Ganos C, Ogrzal T, Schnitzler A, Münchau A. The pathophysiology of echopraxia/echolalia: relevance to Gilles de la Tourette syndrome. Mov Disord 2012 ;10:1222-1229.
Winum JY, Poulsen SA, Supuran CT. Therapeutic ap- plications of glycosidic carbonic anhydrase inhibitors. Med Res Rev 2009;29:419-435.
McElroy SL, Guerdjikova AI, Martens B, et al. Role of antiepileptic drugs in the management of eating disor- ders. CNS Drugs 2009;23:139-156.
Jones MW. Topiramate safety and tolerability.Can J Neurol Sci 1998;25:S13-15.
Sachdeo RC. Topiramate. Clinical profile in epilepsy. Clin Pharmacokinet 1998;34:335- 346.
Chung AM, Reed MD. İntentional Topiramate Inges- tin in an Adolescent Female. Ann Fharmacother 2004;38:1439-1442.
Sankar R, Holmes GL: Mechanisms of action for the commonly used antiepileptic drugs: Relevance to an- tiepileptic drug-associated neurobehavioral adverse effects. J Child Neurol 2004;19: 6-14.
Bourgeois BF. New antiepileptic drugs. Curr Opin Pedi- atr 1998;8:543-548.
Langtry HD, Gillis JC, Davis R. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in themanagement of epilepsy. Drugs 1997;54:752-773.
Lu Y, Wang X, Li Q, et al .Tolerability and safety of topiramate in Chinese patients with epilepsy an open- label, long-term, prospective study. Clin Drug Investig 2007;27:683-690.
Doose DR, Walker SA, Gisclon LG, Nayak RK. Sin- gle-dose pharmacokinetics and effect of food on the bioavailability of topiramate, novel antiepileptic drug. J Clin Pharmacol 1996;36:884-891.
Rosenfeld WE, Liao S, Kramer LD, et al. Compari- son of the steady-state pharmacokinetics of topira- mate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997;3:324-333.
Fakhoury T, Murray L, Seger D, et al. Topiramate overdose: clinical and laboratory features. Epilepsy Behav 2002;3:185-189
Smith AG, Brauer HR, Catalano G, Catalano MC. Topiramate overdose: a case report and literature re- view. Epilepsy Behav 2001;2:603-607.